95 related articles for article (PubMed ID: 7718859)
1. The autocrine regulatory effect of vasoactive intestinal peptide on the growth of human pancreatic carcinoma cells.
Chen Y; Chen Q; Lu G; Fan Z; Zhong S
Chin Med Sci J; 1994 Dec; 9(4):215-9. PubMed ID: 7718859
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
3. Effects of vasoactive intestinal peptide on adenosine 3',5'-monophosphate, ornithine decarboxylase, and cell growth in a human colon cell line.
Yu D; Seitz PK; Selvanayagam P; Rajaraman S; Townsend CM; Cooper CW
Endocrinology; 1992 Sep; 131(3):1188-94. PubMed ID: 1324153
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide receptor antagonist [4Cl-D-Phe6, Leu17] VIP.
Pandol SJ; Dharmsathaphorn K; Schoeffield MS; Vale W; Rivier J
Am J Physiol; 1986 Apr; 250(4 Pt 1):G553-7. PubMed ID: 2421587
[TBL] [Abstract][Full Text] [Related]
5. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.
Zia H; Leyton J; Casibang M; Hau V; Brenneman D; Fridkin M; Gozes I; Moody TW
Life Sci; 2000; 66(5):379-87. PubMed ID: 10670826
[TBL] [Abstract][Full Text] [Related]
6. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW
Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916
[TBL] [Abstract][Full Text] [Related]
8. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.
Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P
Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal polypeptide inhibits c-myc expression and growth of human gastric carcinoma cells.
Kim SW; Beauchamp RD; Townsend CM; Thompson JC
Surgery; 1991 Aug; 110(2):270-5; discussion 276. PubMed ID: 1713357
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid hormone (PTH) and PTH-related peptide induce relaxation of smooth muscle cells from guinea pig ileum: interaction with vasoactive intestinal peptide receptors.
Botella A; Rekik M; Delvaux M; Davicco MJ; Barlet JP; Frexinos J; Bueno L
Endocrinology; 1994 Nov; 135(5):2160-7. PubMed ID: 7525262
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide increases VEGF expression to promote proliferation of brain vascular endothelial cells via the cAMP/PKA pathway after ischemic insult in vitro.
Yang J; Shi QD; Song TB; Feng GF; Zang WJ; Zong CH; Chang L
Peptides; 2013 Apr; 42():105-11. PubMed ID: 23340020
[TBL] [Abstract][Full Text] [Related]
12. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
13. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
Rekasi Z; Varga JL; Schally AV; Halmos G; Armatis P; Groot K; Czompoly T
Endocrinology; 2000 Jun; 141(6):2120-8. PubMed ID: 10830299
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide receptor regulation and reversible desensitization in human colonic carcinoma cells in culture.
Boissard C; Marie JC; Hejblum G; Gespach C; Rosselin G
Cancer Res; 1986 Sep; 46(9):4406-13. PubMed ID: 3015387
[TBL] [Abstract][Full Text] [Related]
15. Elevation of intracellular cAMP by noradrenaline and vasoactive intestinal peptide in striated ducts isolated from the rabbit mandibular salivary gland.
Evans RL; Perrott MN; Lau KR; Case RM
Arch Oral Biol; 1996 Jul; 41(7):689-94. PubMed ID: 9015570
[TBL] [Abstract][Full Text] [Related]
16. The autocrine function of vasoactive intestinal peptide on human neuroblastoma cell growth and differentiation.
Pence JC; Shorter NA
Arch Surg; 1993 May; 128(5):591-5. PubMed ID: 8387768
[TBL] [Abstract][Full Text] [Related]
17. Effect of vasoactive intestinal peptide on gastric adenocarcinoma.
Li GH; Qian W; Song GQ; Hou XH
J Gastroenterol Hepatol; 2007 Aug; 22(8):1328-35. PubMed ID: 17559364
[TBL] [Abstract][Full Text] [Related]
18. [Inhibition by VIP of the proliferation of pancreatic cancer cells].
Yao CZ
Zhonghua Wai Ke Za Zhi; 1989 Jan; 27(1):42-4, 62. PubMed ID: 2550185
[TBL] [Abstract][Full Text] [Related]
19. Promotion of differentiation in human colon carcinoma cells by vasoactive intestinal polypeptide.
Hoosein NM; Black BE; Brattain DE; Brattain MG
Regul Pept; 1989 Jan; 24(1):15-26. PubMed ID: 2544928
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide stimulates immunoglobulin production and growth of human B cells.
Ishioka C; Yoshida A; Kimata H; Mikawa H
Clin Exp Immunol; 1992 Mar; 87(3):504-8. PubMed ID: 1311995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
